About
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Current Value
$1.251 Year Return
Current Value
$1.251 Year Return
Key Details
Market Cap
$92.28M
P/E Ratio
-0.55
1Y Stock Return
-91.61%
1Y Revenue Growth
-
Dividend Yield
0.00%
Price to Book
0.3
Strategies that include ZNTL
Double maintains 1 strategies that include ZNTL - Zentalis Pharmaceuticals, Inc.
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Stock's related to ZNTL
The stocks that are correlated to ZNTL - Zentalis Pharmaceuticals, Inc. are CRBU, NGNE, ADPT, FATE, GSAT
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 44.05% | $73.01M | -82.71% | 0.00% | |
N NGNENeurogene, Inc. | 42.70% | $144.37M | -77.32% | 0.00% |
| 39.23% | $1.10B | +171.43% | 0.00% | |
| 39.20% | $77.93M | -90.24% | 0.00% | |
G GSATGlobalstar, Inc. | 36.82% | $2.48B | -1.50% | 0.00% |
| 36.20% | $257.23M | -69.00% | 0.00% | |
| 36.15% | $592.86M | -77.74% | 0.00% | |
| 36.13% | $606.82M | -22.75% | 0.00% | |
G GPROGoPro, Inc. | 35.82% | $86.27M | -74.03% | 0.00% |
| 33.96% | $126.60M | -41.18% | 0.00% | |
I INMDInMode Ltd. | 33.93% | $1.13B | -17.80% | 0.00% |
| 33.60% | $3.90B | +29.93% | 0.00% | |
| 33.53% | $1.54B | -34.63% | 0.00% | |
L LAWCS Disco, Inc. | 33.47% | $232.48M | -51.81% | 0.00% |
| 33.16% | $1.64B | -43.30% | 0.00% | |
| 32.95% | $697.83M | -65.05% | 0.00% | |
| 32.95% | $1.36B | -62.39% | 0.00% | |
| 32.73% | $299.83M | -65.93% | 0.00% | |
| 32.64% | $622.79M | -52.50% | 0.00% | |
| 32.57% | $2.80B | -49.80% | 0.00% | |
ETF's related to ZNTL
The ETFs that are correlated to ZNTL - Zentalis Pharmaceuticals, Inc. are IBB, GNOM, XBI, ARKG, BBH
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 44.92% | $5.70B | 0.45% | |
| 41.85% | $48.48M | 0.5% | |
X XBISPDR Biotech ETF | 41.68% | $5.06B | 0.35% |
| 41.02% | $987.53M | 0.75% | |
| 40.38% | $362.92M | 0.35% | |
| 39.81% | $48.65M | 0.69% | |
| 38.98% | $112.39M | 0% | |
| 37.08% | $229.13M | 0.58% | |
| 36.68% | $294.73M | 0% | |
| 35.18% | $1.09B | 0.56% | |
| 33.95% | $809.63M | 0.6% | |
| 33.33% | $158.44M | 0.35% | |
| 30.80% | $63.84B | 0.19% | |
| 30.71% | $11.24B | 0.07% | |
| 30.67% | $315.74M | 0.68% | |
| 30.38% | $11.04B | 0.24% | |
| 30.11% | $16.30B | 0.09% | |
| 30.00% | $10.93B | 0.24% | |
| 29.87% | $2.68B | 0.084% | |
| 29.75% | $1.24B | 0.1% | |
News
Yahoo
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to three (3) newly hired em
Yahoo
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis®
Finnhub
Zentalis Pharmaceuticals Inc: * ZENTALIS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250MILLION - SEC FILINGSource text:Further company coverage: ...
Yahoo
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutic
Finnhub
SAN DIEGO - Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and...
Yahoo
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026 Company also presents preclinical combination data of azenosertib with microtubule
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds